More action on Ariad's '516 patent
Further to discussion about Ariad's US patent 6,410,516, the AP reported on April 13:
Ariad Pharmaceuticals Inc. said late Friday [April 13] it filed a counter claim against Amgen Inc. over the patent to methods of treating human disease by regulating NF-(kappa)B cell-signaling activity.
The claim _ which is also against drug maker Wyeth _ is a response to a lawsuit filed by Amgen against Ariad, saying the company's claims to the patent are invalid and Amgen has not infringed on those patents with its drugs Enbrel and Kineret.
The '516' patent is the patent being disputed. Ariad said the patent, which it claims license to, does not expire until 2019.
Ariad Pharmaceuticals Inc. said late Friday [April 13] it filed a counter claim against Amgen Inc. over the patent to methods of treating human disease by regulating NF-(kappa)B cell-signaling activity.
The claim _ which is also against drug maker Wyeth _ is a response to a lawsuit filed by Amgen against Ariad, saying the company's claims to the patent are invalid and Amgen has not infringed on those patents with its drugs Enbrel and Kineret.
The '516' patent is the patent being disputed. Ariad said the patent, which it claims license to, does not expire until 2019.
posted by Lawrence B. Ebert at 9:42 AM
0 Comments:
Post a Comment
<< Home